中国肺癌杂志2011，Vol.14Issue(4)：351-357,7.DOI:10.3779/j.issn.1009-3419.2011.04.09
吉非替尼治疗非小细胞肺癌的meta分析
Gefitinib for Non-small Cell Lung Cancer:A meta Analysis
摘要
Abstract
Background and objective Malignant grade and death rate are ,very high for non-small cell lung cancer, and gefitinib is a new molecule target anticancer drug.The aim of this meta analysis is to evaluate the clinical efficacy and safety of gefitinib for non-small cell lung cancer.Methods We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library, Issue 8, 2010), PubMed (1966-2010.8), EMBASE (1974-2010.8), CNKI (1994-2010.8), VIP (1989-2010.8), and CMD Digital Periodicals (1998-2010.8).Two reviewers independently evaluated the quality of the included studies and extracted the data.Meta-analyses were performed by RevMan 5.0 software.Results Thirteen randomized controlled trials (RCTs) involving 6,207 patients were included.The results of meta-analyses showed that: gefitinib showed no remarkable advantage in media survival time, 1 year survival rate, complete response rate (CRR), partial response rate (PRR), stable disease (SD) when compared to Placebo, Docetaxel, Cisplatin+Docetaxel, Pemetrexed.Gifitinib could increase overall survival rate compared to Docetaxel, Cisplatin+Docetaxel (RR=1.41, 95％CI: 1.10-1.80; RR=1.93, 95％: 1.26-2.94).When compared to Placebo, Docetaxel, gifitinib could improve life quality of Total-FACT-L improve rate (RR=1.42, 95％CI: 1.16-1.74; RR=1.66, 95％CI: 1.39-1.97).The major adverse event for gifitinib were rash/acne, dry skin, diarrhea.While gifitinib showed lower hematology toxicity.Conclusion Gifitinib shows more superiority for non-small cell lung cancer, and its clinical application is worthy to be advocated.关键词
吉非替尼/肺肿瘤/Meta分析Key words
Gefitinib/ Lung neoplasms/ Meta analysis分类
医药卫生引用本文复制引用
郭继武,马彬,周慧银,王瑶,张圆..吉非替尼治疗非小细胞肺癌的meta分析[J].中国肺癌杂志,2011,14(4):351-357,7.基金项目
本研究受兰州大学2010教学研究项目(No.201022)和兰州大学循证医学中心"循证医学创新项目"(No.2010LDFBM-B)资助 （No.201022）
